Clostridium-derived quorum sensing peptide, preparation method and use
By extracting and preparing GIVL population sensing peptides from Clostridium phacodonite, the shortcomings of diabetes treatment in the prior art were solved, and the effect of significantly reducing blood sugar levels was achieved, and a new treatment plan was provided.
Patent Information
- Application Number
- PCT/CN2024/078002
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-02-22
- Publication Date
- 2024-11-28
AI Technical Summary
The existing population sensing peptides are mainly concentrated in antibacterial aspects, and there is a lack of effective treatment plans for chronic diseases such as diabetes.
A population sensing peptide called GIVL was extracted and prepared from C. phacodonidae, which has α-glucosidase inhibition and lowered blood glucose activity. The peptide was prepared by fermentation and solid-phase synthesis, combining C. phacodonidae, and the peptide was prepared by fermentation and solid-phase synthesis, combining C. phacodonidae. As a drug or food for the treatment or adjuvant treatment of diabetes.
GIVL significantly reduces blood sugar levels in type 2 diabetic mice, has good biocompatibility and low side effects, providing a new potential treatment for diabetes.
Smart Images

Figure CN2024078002_28112024_PF_FP_ABST
Abstract
Description
A quorum sensing peptide derived from Clostridium, preparation method and application Technical Field
[0001] The present invention belongs to the fields of biotechnology and medicine, and relates to a quorum sensing peptide derived from Clostridium, a preparation method and an application thereof. Background Art
[0002] Small molecule metabolites are essential for microbial growth, communication, division, and survival. In addition to their known roles in microorganisms, recent studies have revealed that some metabolites, such as short-chain fatty acids, bile acids, and peptides, can interact with and influence host biological functions. Among these metabolites, peptides secreted by microorganisms are particularly noteworthy due to their structural and functional diversity. For example, peptides from human oral actinomycetes exhibit potent antibacterial activity against Streptococcus pneumoniae by specifically inhibiting bacterial cell wall biosynthesis. In addition to inhibiting pathological organisms, there is emerging evidence that microbial peptides are attractive candidates for treating various diseases, including cancer and diabetes.
[0003] Quorum sensing peptides (QSPs), derived from quorum sensing systems, are crucial for microbial communication, enabling them to sense and respond to environmental changes. In addition to serving as communication molecules between microorganisms, QSPs are increasingly recognized for their unprecedented impact on host physiological and pathological processes by modulating inflammation and the immune system. The low molecular weight, cell-penetrating ability, and ease of communication between cells and the host make QSPs ideal candidates for therapeutic applications. For example, the Bacillus subtilis signal peptide fengycin can prevent severe pathological Staphylococcus aureus infections by inhibiting intestinal colonization. Furthermore, lipopeptides extracted from Bacillus subtilis not only exhibit antimicrobial effects by inhibiting Enterococcus faecalis Fsr (fecal streptococcal regulator) but also help enhance immune responses to such infections. These findings suggest that QSPs are promising signaling molecules with important applications in host-centric applications. To date, numerous bacterial quorum sensing peptides have been identified, and the structure and function of some have been characterized. Patent CN201910862017.0 discloses an active peptide for the quorum sensing system of Vibrio harveyi. This active peptide can be used to guide the development of new antimicrobial agents, which is of great significance to human health and agricultural development. It is worth noting that the functions of most QSPs are still concentrated in antibacterial aspects. However, due to the optimization of QSPs in the long-term competition and co-evolution between microorganisms, such as the addition of lactones, thiolactones, lanthanides or isopentene entities, their structures and functions are diverse. Therefore, in theory, a large number of potential QSPs from microorganisms can serve as a source of candidate substances for the treatment of various diseases other than infections (such as chronic diseases).
[0004] Clostridium (Clostridium) is a type of Gram-positive, anaerobic bacteria with a spindle-shaped body. Clostridium is widely found in soil, water, and the intestines of humans and animals, and is an important member of the human intestinal flora. Clostridium is a resident bacteria in the intestinal flora and plays an important role in the balance of the human intestinal ecosystem. Clostridium tyrobutyricum, a species of Clostridium, is a non-pathogenic bacterium that has been isolated from various dairy products and the feces of cattle, humans, and infants. Compared with other probiotics, Clostridium tyrobutyricum has unparalleled advantages in industrial production. It can naturally produce short-chain fatty acids (SCFAs) such as acetate and butyrate, repairing damaged intestinal mucosa and restoring the balance of the microbiome. In addition, butyrate, a metabolite produced by acid-producing bacteria such as Clostridium tyrobutyricum, can effectively lower blood sugar levels by promoting postprandial insulin secretion, making it a potential treatment for diabetes. In addition to producing short-chain fatty acids, Clostridium tyrobutyricum can also secrete signal peptides during its growth through the quorum sensing mechanism, inhibiting the growth and reproduction of pathogenic microorganisms and regulating the balance of intestinal microbial flora, thereby affecting the host's nutritional status, physiological functions, stress response, etc.
[0005] Summary of the Invention
[0006] The present invention provides a quorum sensing peptide derived from Clostridium, a preparation method, and its application. The quorum sensing peptide has α-glucosidase inhibition and blood sugar lowering activity, and has broad application prospects as a drug, health product, or food for treating hyperglycemia and type 2 diabetes.
[0007] The technical solution adopted in the present invention is:
[0008] The present invention provides a quorum sensing peptide derived from Clostridium, having an amino acid sequence as shown in SEQ ID NO. 1 (GIVLVPTSLVSG), or an amino acid sequence having at least 50% sequence identity to SEQ ID NO. 1. The peptide is a single-stranded linear structure, appears as a white powder, and is poorly soluble in water, designated GIVL. The Clostridium is Clostridium tyrobutyricum, strain number ATCC 25755, deposited with the American Type Culture Collection.
[0009] The present invention also provides a nucleic acid molecule encoding the quorum sensing peptide with the amino acid sequence of SEQ ID NO.1, and the nucleotide sequence thereof is shown as SEQ ID NO.2.
[0010] The present invention also provides a nucleic acid molecule for secreting and post-translationally modifying the quorum sensing peptide having an amino acid sequence of SEQ ID NO.1, and the nucleotide sequence thereof is shown in SEQ ID NO.3.
[0011] The present invention also provides a method for preparing a quorum sensing peptide derived from Clostridium, which includes two methods:
[0012] One method is to prepare the quorum sensing peptide GIVL by fermenting Clostridium tyrobutyricum, comprising the following steps:
[0013] Step 1, fermentation and collection of fermentation broth: a single colony of Clostridium tyrobutyricum ATCC 25755 was picked, inoculated into liquid enriched Clostridium culture medium (RCM), cultured for 24 to 36 hours, and then inoculated into a fermentor containing fermentation medium. The fermentation time was 24 to 120 hours, and the cell-free supernatant was collected by centrifugation;
[0014] Step 2, pretreatment: add acid solution to the supernatant, let it stand at 4°C for 8-16 hours, collect the precipitate by centrifugation, dry it under ventilation, grind it to obtain the precipitate powder, add methanol to obtain the filtrate containing the quorum sensing peptide;
[0015] Step 3, reversed-phase chromatography separation and semi-preparative: Desalt the product using pure methanol using a ReSource reversed-phase column. The filtrate obtained in step 2 was loaded onto the column and the fractions corresponding to the elution peak were collected.
[0016] Step 4, separation, purification and structural identification: The components separated in step 3 were filtered, desalted and concentrated by nanofiltration, and then separated and purified by HILIC chromatography. The collected components were freeze-dried and analyzed and identified by Nano-LC-ESI-MS / MS to obtain the quorum sensing peptide GIVL.
[0017] Another method is to prepare the quorum sensing peptide GIVL by solid phase synthesis, comprising the following steps:
[0018] Step 1, resin activation: starting from the C-terminal An, the resin is placed in the reaction column and soaked;
[0019] Step 2, deprotection: After the resin is soaked, the solution is removed and deprotection reaction is carried out with piperidine;
[0020] Step 3, weighing materials: weighing the amino acids, condensing agent and N-methylmorpholine required for the next step;
[0021] Step 4, deprotection: After deprotection is completed, wash with dimethylformamide, detect the deprotection color, and record it;
[0022] Step 5, adding materials: After the detection is completed, add the amino acid in step 3, then add the reaction solution, base and N-methylmorpholine in sequence, adjust the gas uniformly, and start the reaction;
[0023] Step 6, detection: After the reaction is completed, the reaction liquid is removed, washed with dimethylformamide, and then tested to see if the reaction is complete;
[0024] Step 7: If the reaction is complete, repeat steps 2 to 6 to connect the next amino acid; if the reaction is not complete, soak the resin in dichloromethane without eluting the protection, and continue to connect the amino acid in this step until it is connected.
[0025] The application of the present invention includes the following three aspects:
[0026] On the one hand, the use of quorum sensing peptides derived from Clostridium or nucleic acid molecules encoding the quorum sensing peptides in the above scheme in drugs and foods for the treatment or auxiliary treatment of diabetes, especially in the application of type 2 diabetes, has a significant effect. In vitro enzymatic experiments have verified that the quorum sensing peptide GIVL has good α-glucosidase inhibitory activity, IC 50 Further in vivo pharmacodynamic experiments demonstrated that the quorum sensing peptide GIVL can significantly reduce the blood glucose level in type 2 diabetic mice, which provides new possibilities for the treatment of diabetes and other related diseases.
[0027] On the other hand, the use of Clostridium tyrobutyricum producing the quorum sensing peptide in medicines, health products or foods for treating diabetes, especially in type 2 diabetes, has a significant effect.
[0028] On the other hand, the use of a composition comprising the quorum sensing peptide and Clostridium tyrobutyricum that produces the quorum sensing peptide in medicines and foods for the treatment or auxiliary treatment of diabetes, especially in the application of type 2 diabetes, has a significant effect. Quorum sensing peptide GIVL, as a natural product, is derived from the probiotic Clostridium tyrobutyricum and has the characteristics of regulating blood sugar and insulin sensitivity. Clostridium tyrobutyricum is a living bacterium that can colonize in the intestine and regulate the balance of intestinal flora, improve the microecological environment, and has a significant hypoglycemic effect. Compared with existing therapies, the composition of quorum sensing peptide GIVL and Clostridium tyrobutyricum may have better biocompatibility, lower side effects and better therapeutic effects. At the same time, the composition can be used as a new type of health product, medicine or food for the treatment of diseases such as diabetes, and has broad market prospects and economic value.
[0029] Beneficial effects of the present invention:
[0030] 1. This study, using Clostridium tyrobutyricum as the research subject, identified the quorum sensing signal peptide GIVL for the first time from the supernatant of C. tyrobutyricum fermentation broth through mass spectrometry and gene editing. In vitro enzymatic experiments demonstrated that the quorum sensing peptide exhibited α-glucosidase inhibitory activity, and in vivo pharmacodynamic experiments further confirmed that the quorum sensing peptide also exhibited a blood sugar-lowering effect. GIVL is easy to synthesize, safe, and non-toxic. It has promising potential and application prospects for the development of special medical foods, health products, and pharmaceuticals for the treatment or adjunctive treatment of type 2 diabetes.
[0031] 2. The probiotic Clostridium tyrobutyricum provided by the present invention can colonize in the intestine and regulate the balance of intestinal flora, improve the intestinal microecological environment, and has a significant blood sugar lowering effect.
[0032] 3. The present invention provides a health product, medicine, or food composition comprising GIVL and Clostridium tyrobutyricum for treating diseases such as diabetes. This composition can be used as a novel health product, medicine, or food for treating diseases such as diabetes, and has broad prospects and economic value. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 is a liquid chromatography-mass spectrometry (LC-MS) of GIVL in Example 1: (a) primary mass spectrum of a GIVL standard; (b) liquid chromatography of a predicted QSP in the supernatant of Clostridium tyrobutyricum; (c) ion fragmentation of a primary mass spectrum of a predicted QSP in the supernatant of Clostridium tyrobutyricum; (d) secondary mass spectrum of a predicted QSP in the supernatant of Clostridium tyrobutyricum; (e) secondary mass spectrum of the corresponding GIVL standard;
[0034] Figure 2 shows the levels of GIVL in the supernatants of wild-type and mutant Clostridium tyrobutyricum in Example 2; (a) Wild-type and mutant Clostridium tyrobutyricum were cultured separately, and GIVL was analyzed by orbitrap high-resolution liquid spectrometry-mass spectrometry (LC-HRMS); (b) Quantitative analysis of GIVL levels in wild-type and mutant Clostridium tyrobutyricum; (c) GIVL synthesis in cell culture is related to time and bacterial concentration;
[0035] FIG3 is a graph showing the results of GIVL inhibiting α-glucosidase in Example 3;
[0036] FIG4 is a kinetic curve of GIVL inhibition of α-glucosidase in Example 4;
[0037] Figure 5 shows the improvement of glucose-insulin homeostasis of T2D mice by GIVL in Example 6; (a) fasting blood glucose levels in each intervention group; (b) fasting insulin levels in each intervention group; (c) oral glucose tolerance test (OGTT) in each intervention group; (d) insulin tolerance test (ITT) in each intervention group;
[0038] Figure 6 shows the composition of the intestinal microbiome regulated by GIVL in Example 7; (a) relative abundance of intestinal flora at the order level in each intervention group; (b) LEfSe analysis identified genomic features (taxonomic groups) to characterize the significant differences in the microbial communities between the intervention groups, and the histogram of LDA scores showed species with LDA scores greater than the set threshold (the default was 4 groups); (c) relative abundance of Dysosmobacter in each intervention group; (d) concentration of short-chain fatty acids (SCFAs) in feces of each intervention group; (e) detection of GIVL and short-chain fatty acid levels of wild-type and mutant Clostridium tyrobutyricum in serum bottle cultures.
[0039] FIG7 shows that Clostridium tyrobutyricum reduces the fasting blood glucose level of diabetic mice in Example 8. DETAILED DESCRIPTION
[0040] The advantages and various effects of the present invention will be more clearly presented below in conjunction with specific embodiments and examples. It should be understood by those skilled in the art that these specific embodiments and examples are only for illustrating the present invention and are not intended to limit the scope of the present invention in any way.
[0041] Example 1 Preparation of Quorum Sensing Peptide GIVL and Structural Identification of GIVL in Fermentation Broth of Clostridium tyrobutyricum ATCC 25755
[0042] (1) Method for extracting quorum sensing peptide GIVL from Clostridium tyrobutyricum fermentation broth
[0043] Step 1: Pick 4 single colonies of Clostridium tyrobutyricum (ATCC 25755), inoculate them into 50 mL of Clostridium fortified medium, and culture with low-speed shaking for 24 h until OD 600 ~2.0, the activated Clostridium tyrobutyricum was inoculated into a 5 L fermentor containing liquid fermentation medium (CGM) (inoculation amount was 5%), the fermentation conditions were 37°C, 200 rpm, pH = 6, the fermentation time was 100 h, and the cell-free supernatant was collected by centrifugation at 12000×g for 15 min;
[0044] Step 2: Pretreatment: add acid solution to the above supernatant to adjust the pH to 1.8, stand at 4°C for 16 hours, centrifuge and discard the supernatant, collect the precipitate, and dry the precipitate at 50°C for 20 hours. After grinding, obtain the precipitate powder, and add methanol to obtain the filtrate containing the quorum sensing peptide;
[0045] Step 3, reversed-phase chromatography separation and semi-preparative separation: Use a ReSource reversed-phase column to desalt with pure methanol until the baseline is stable. Equilibrate with 5 mL of equilibration solution. The system automatically adds sample (injection volume 500 μL) and elutes with 0.1% TFA in methanol at a flow rate of 0.5 mL / min. Collect the fractions corresponding to the elution peak, concentrate with a rotary evaporator, and store frozen.
[0046] Step 4, separation, purification and structural identification: The components separated in step (3) were filtered (0.22 μm filter) and then separated and purified by HILIC chromatography on a Waters high performance liquid chromatograph. 5 mL of eluent A was used to equilibrate a HILIC column (4.6×250 mm, 5 μm, ), add 30 μL of sample, and perform linear elution at a flow rate of 1 mL / min for 20 minutes, collecting the eluate every 2 minutes. Freeze-dry at -60°C for 36 hours to obtain the quorum sensing peptide product. The obtained quorum sensing peptide product was analyzed and identified by Nano-LC-ESI-MS / MS, which confirmed the peptide GIVL as having hypoglycemic activity.
[0047] (2) Solid-phase synthesis of GIVL
[0048] Synthesis of the GIVL standard: The amino acid sequence of the GIVL standard is Gly-Ile-Val-Leu-Val-Pro-Thr-Ser-Leu-Val-Ser-Gly. It was synthesized by Shanghai Jier Biochemical Co., Ltd. via solid-phase synthesis from the C-terminus (carboxyl terminus) to the N-terminus (amino terminus). The resulting quorum sensing peptide GIVL had a purity of 98.62% as determined by HPLC, and its exact molecular weight was determined by ESI-MS. The specific preparation process is as follows:
[0049] 1. Resin activation: Starting from the C-terminal An, weigh the required amount of resin Fmoc-An-Resin and place it into the reaction column to soak for 30 minutes;
[0050] 2. Deprotection: After the resin is soaked for 30 minutes, the solution is removed and then deprotection is carried out using piperidine for 30 minutes;
[0051] 3. Weighing materials: Within 30 minutes of deprotection, calculate the amount of amino acid, condensing agent, and N-methylmorpholine required for each step based on the amount made, and then weigh the next amino acid Fmoc-An-1;
[0052] 4. Deprotection: After 30 minutes of deprotection, remove the piperidine and wash with dimethylformamide 6 times. After 6 washes, detect the deprotection color and record it;
[0053] 5. Adding materials: After washing, deprotection and detection, add the weighed materials in the order of each peptide, then add a small amount of reaction solution, then add base and N-methylmorpholine, adjust the gas evenly, use dichloromethane to flush away the resin stuck on the inner wall of the reaction column, and then record the reaction time, which is 30 minutes;
[0054] 6. Detection: After 30 minutes of reaction, remove the reaction solution, wash it with dimethylformamide 3 times, and then detect whether the reaction is complete;
[0055] 7. After the connection is detected, repeat steps 2 to 6 to connect the next amino acid. If it fails the test, soak it in dichloromethane, then continue to connect the amino acid in this step without deprotection until it is connected.
[0056] (2) Preparation of cell-free supernatant of Clostridium tyrobutyricum ATCC 25755
[0057] Clostridium tyrobutyricum ATCC 25755 stored at -80°C was inoculated into Reinforced Clostridium Medium (RCM), cultured anaerobically at 37°C for 36 hours, and then subcultured once. The inoculum was then inoculated into a 5L fully automated mechanically stirred fermenter containing 950mL of liquid fermentation medium (Clostridium Growth Medium, CGM) at a 5% inoculum volume (v / v). The temperature, pH, and stirring speed were set at 37°C, 6.0, and 150 rpm, respectively, for 92 hours. During the fermentation process, samples were taken every 4 hours, centrifuged at 12,000 rpm for 15 minutes at 4°C, and the supernatant was collected and stored at 4°C for later use.
[0058] The Reinforced Clostridium Medium (RCM) contains the following components (1 L system): 5 g glucose, 5 g NaCl, 10 g peptone, 10 g beef powder, 3 g yeast extract, 3 g anhydrous sodium acetate, 1 g soluble starch, 0.5 g cysteine hydrochloride, the solvent is water, and the pH is natural;
[0059] The fermentation medium (Clostridium Growth Medium, CGM) contains the following components (1L system): 60g glucose, 40g calcium carbonate, 5g tryptone, 3g yeast extract powder, 5g NaCl, 2g (NH4)2SO4, 1g K2HPO4, 0.5g KH2PO4, 0.1g MgSO4·7H2O, 0.03g FeSO4·7H2O, the solvent is water, and the pH is natural.
[0060] (3) Preparation and detection of the supernatant to be tested
[0061] 1 mL of the cell-free supernatant was desalted using Pierce C18 Tips (Thermo Fisher Scientific Inc., Massachusetts, USA), eluted with 80% acetonitrile and filtered through a Millipore PVDF 0.22 μm membrane to obtain the supernatant to be tested.
[0062] The desalting and elution steps are as follows: ① Activation: First, rinse the extraction column with 5 mL of methanol, then rinse the column with 5 mL of deionized water to wet it. ② Loading: Evenly pass the cell-free supernatant through the extraction column at a constant flow rate, repeat three times. ③ Washing: Remove water-soluble salts with 4 mL of deionized water. ④ Elution: Elution with 1 mL of 80% acetonitrile in batches, repeat four times.
[0063] Detection conditions: using a Hypersil GOLD VANQUISH column C18 ( Compounds were separated using a Vanquish UPLC system (Thermo Scientific, Germany) (100 × 2.1 mm ID, 1.9 μm). Mass spectrometric analysis was performed on a Q Exactive plus mass spectrometer (Thermo Fisher Scientific, Germany) equipped with an electrospray ionization (ESI) source. Solvent A consisted of 0.1% formic acid (v / v) in water, and solvent B consisted of acetonitrile containing 0.1% formic acid (v / v). The supernatant was eluted using the following gradient at a flow rate of 0.3 ml / min: 10% solvent B (0–20 min), 80% solvent B (20–25 min), and 10% solvent B (25–35 min).
[0064] Detection Conclusions: The supernatant was analyzed using Orbitrap high-resolution liquid chromatography-mass spectrometry (LC-HRMS). The results are as follows: (i) A dominant peak with a liquid phase retention time of 7.02 minutes and a mass-to-charge ratio (m / z) of 1142.68113 was detected in the supernatant of wild-type C. tyrobutyricum (Figures 1b and 1c). (ii) The bn and yn ions produced by induced dissociation of the parent ion were consistent with those of the standard GIVL (Figures 1d and 1e). The molecular formula was GIVLVPTSLVSG (abbreviated as GIVL), which was confirmed by accurate mass measurement. These results confirm the presence of GIVL in C. tyrobutyricum.
[0065] Example 2 Verification that GIVL is a quorum sensing peptide of Clostridium tyrobutyricum
[0066] (1) In Gram-positive bacteria, agrD is the precursor for encoding QSPs, and agrB is responsible for the secretion and post-translational modification of QSPs. Therefore, the nucleotide sequences encoding agrD and agrB in Clostridium tyrobutyricum ATCC 25755 were aligned based on the published genes encoding the quorum sensing peptides agrD and agrB of Gram-positive bacteria.
[0067] By searching the NCBI database and combining the coding and modified sequences of published Gram-positive clostridium quorum sensing signal peptides, the coding gene (CTK_C12140) encoding the quorum sensing signal peptide of Clostridium tyrobutyricum ATCC 25755 and the corresponding nucleotide sequence were compared and analyzed as shown in SEQ ID NO.2, and the gene (CTK_C12160) responsible for modifying the quorum sensing signal peptide of Clostridium tyrobutyricum ATCC 25755 and the corresponding nucleotide sequence were compared and analyzed as shown in SEQ ID NO.3.
[0068] (2) Construction of ΔagrD and ΔagrB knockout strains of Clostridium tyrobutyricum;
[0069] The recombinant plasmids pMTL82151-agrD and pMTL82151-agrB were constructed by targeting the CTK_C12140 gene encoding agrD and the CTK_C12160 gene encoding agrB of Clostridium tyrobutyricum with 5'-TCA-3' as the PAM sequence and a 38-bp spacer sequence; a lactose-inducible promoter derived from the plasmid pClone EZ-Plac-repeat; a terminator derived from Clostridium tyrobutyricum; and 500-bp homology arms upstream and downstream of the agrD and agrB genes from the Clostridium tyrobutyricum genome. The specific construction process is as follows:
[0070] 1) Design primers to amplify the lactose-inducible promoter, partial repeat sequence, spacer sequence, repeat sequence, terminator, and upper and lower homologous arms of the target gene, respectively. Connect these fragments by PCR to form a gene fragment of 2461 bp in size.
[0071] 2) Plasmid pMTL82151 was double-digested with NotI and AatII, respectively, and ligated with the gene fragment from step 1) via Gibson seamless cloning. The ligation product was transformed into Escherichia coli DH5α via heat shock transformation and cultured at 37°C for 36 h. Single colonies were picked, and plasmids were extracted. Correct transformants were selected for sequencing verification, and plasmids were extracted and named pMTL82151-agrD and pMTL82151-agrB, respectively.
[0072] 3) The recombinant plasmid obtained in step 2) was transferred into Clostridium tyrobutyricum ATCC 25755 by conjugation. The specific steps were as follows: the recombinant plasmids pMTL82151-agrD and pMTL82151-agrB were heat-shocked and transformed into Escherichia coli CA434, and positive clones were screened using a double-antibody LB solid plate (containing 25 mg / mL chloramphenicol and 50 mg / mL kanamycin). The positive clones were then cultured in LB liquid medium containing double-antibody (containing 25 mg / mL chloramphenicol and 50 mg / mL kanamycin) at 37°C and 200 rpm until the OD 600 ~2.0, take 3mL of bacterial solution, 4000rpm, 5min to collect bacteria, use PBS buffer to wash 3 times, then take bacteria, and then mix with 400μL OD 600The clones of Clostridium tyrobutyricum (Ct) at a concentration of 100 μg / mL and a concentration of 2.0 μg / mL were mixed evenly and spread on a non-antibiotic RCM solid plate. The plates were cultured anaerobically at 37°C for 24 h until a single colony was grown. The bacteria on the RCM plate were eluted with 500 μL of fresh RCM liquid medium. The plates were then spread on a double-antibiotic RCM solid plate (containing 25 mg / mL thiamphenicol and 200 mg / mL D-cycloserine) and cultured at 37°C for 72 h. The positive colonies were verified by colony RCR, which were the ΔagrD knockout bacteria or ΔagrB knockout bacteria.
[0073] (3) Construction of agrD complementation strain;
[0074] The agrD (CTK_C12140) gene of the present invention is derived from Clostridium tyrobutyricum ATCC 25755. The agrD gene fragment is amplified using primers Pthl-F and Pthl-R to amplify the thl gene promoter Pthl. Primers 12140-F and 12140-R are used to amplify the gene fragment shown in SEQ ID NO. 2. The PCR reaction conditions and system are as follows:
[0075] Pth1-F is shown in SEQ ID NO.4:
[0076] 5′-NNNGCGGCCGCCTGAATATTCACGAAAATAG-3′
[0077] Pthl-R is shown in SEQ ID NO.5:
[0078] 5′-NNNGACGTCAAATTTAAATTGATTACAAACCTTTTTACC-3′
[0079] 12140-F is shown in SEQ ID NO. 6:
[0080] 5′-GGAGGAATAGTCATGGACGTCATGAAATTTTTAAAAAGTTTCTTTAACAAAA-3′
[0081] 12140-R is shown in SEQ ID NO.7:
[0082] 5′-TGCATGTCTGCAGGCCTCGAGTTACTTTAATAACTCATCAGGGCATTT-3′ PCR reaction system:
[0083] PCR reaction conditions: 94°C, 2 min; 98°C, 10 sec; 55°C, 30 sec; 68°C, 1 min / kb, 25-40 cycles; 68°C, 10 min.
[0084] The plasmid pMTL82151 was double-digested with NotI and AatII, ligated with the promoter Pthl, transformed into Escherichia coli DH5α, and the plasmid was sequenced and verified, and named pMTL82151-Pthl. Similarly, pMTL82151-Pthl was double-digested with AatII and XhoI, ligated with the 12140 gene fragment, transformed into Escherichia coli DH5α, and the plasmid was sequenced and verified, and named pMTL82151-Pthl-12140.
[0085] The enzyme digestion system is:
[0086] The connection system is:
[0087] The recombinant plasmid pMTL82151-Pthl-12140 was also transferred into the Clostridium tyrobutyricum agrD knockout strain by the above-mentioned conjugation transfer method, and the positive colonies were verified by colony PCR to obtain the agrD complemented strain.
[0088] (4) Verification that GIVL is a quorum sensing peptide of Clostridium tyrobutyricum
[0089] In Gram-positive bacteria, agrD encodes the precursor of QSPs. To this end, the endogenous IB CRISPR-Cas system was used to construct an agrD deletion mutant and obtain a ΔagrD knockout strain. Detection of its fermentation products revealed that GIVL was only detectable in the supernatant of the wild-type strain, but not in the ΔagrD knockout strain (Figures 2a and 2b). To further verify that the lack of GIVL was due to the loss of the agrD gene, rather than a genetic compensation reaction caused by gene knockout, a ΔagrD-agrD strain was constructed by genetic complementation of the agrD gene, and its fermentation products were detected. The test results showed that the main peak corresponding to GIVL appeared in the complemented strain, and its level was comparable to that of the wild type (Figures 2a and 2b). This indicates that the agrD gene is responsible for the production of GIVL in Clostridium tyrobutyricum.
[0090] Furthermore, agrB (encoding gene CTK_C12160) is responsible for the secretion and post-translational modification of QSP. Therefore, a ΔagrB knockout strain was constructed, and its fermentation products were tested. Similar to the ΔagrD knockout strain, no GIVL was detected in the fermentation supernatant of the ΔagrB knockout strain (Figures 2a and 2b).
[0091] Experiments have shown that GIVL accumulates slowly in the early stages of wild-type Clostridium tyrobutyricum culture, but accumulates rapidly at cell density OD 600It increased rapidly after reaching a threshold of 3.8 (as shown in Figure 2c), which indicated that the microbial strain induced the secretion of QSPs under high cell density conditions, and the high cell density fermentation technology stimulated the increase in the level of GIVL.
[0092] In summary, the above results prove that GIVL is indeed the quorum sensing peptide of Clostridium tyrobutyricum.
[0093] Example 3 Detection of α-glucosidase inhibitory activity of quorum sensing peptide GIVL
[0094] Principle: A chromogenic substrate method using p-nitrophenyl-α-D-pyranoglucoside (pNPG) as a substrate is used to identify α-glucosidase inhibitors. The principle of this method is that under alkaline conditions, α-glucosidase catalyzes the hydrolysis of the substrate pNPG to generate yellow p-nitrophenol, which has a characteristic absorption peak at a wavelength of 405nm. The amount of pNP produced at 405nm by a microplate reader is used as a criterion for determining the activity of α-glucosidase.
[0095] Methods: A mixture of 20 μL of α-glucosidase solution (0.2 U / mL in 0.1 M PBS, pH 6.8), 20 μL of various concentrations of the test sample solution (quorum sensing peptide GIVL or acarbose at concentrations ranging from 0 to 1 mg / mL in 0.1 M PBS), and 50 μL of PBS (0.1 M, pH 6.8) was added to a 96-well microplate and incubated at 37°C for 10 minutes. Subsequently, the reaction was initiated by the addition of 20 μL of 15 mM pNPG (substrate), incubated at 37°C for an additional 20 minutes, and terminated by the addition of 150 μL of 1 M Na₂CO₃. The release of p-nitrophenol (pNPG) was determined by spectrophotometry at 405 nm using a multi-function plate reader (SpectraMax M2e, Molecular Devices, USA). A control group did not contain the test sample reagents. Under the experimental conditions, the concentration of the substance required to inhibit 50% of the α-glucosidase activity was defined as IC 50 The calculation formula of enzyme activity inhibition rate is:
[0096] Where As and Ab are the absorbance values of the control group and the sample group to be tested respectively. The results are shown in Table 1:
[0097] Table 1 Inhibition rate of α-glucosidase by different concentrations of acarbose and GIVL
[0098] The results are shown in Figure 3, which shows that the quorum sensing peptide GIVL has an inhibition rate of 6.3% to 20.88% on α-glucosidase at a concentration of 0.00782 to 0.0625 mg / mL, which is a low inhibition rate. GIVL has a significantly improved inhibitory activity on α-glucosidase at a concentration of 0.125 to 1 mg / mL. In summary, the above data show that the quorum sensing peptide GIVL has a strong α-glucosidase inhibitory activity and IC 50 The value was 137.85 μM.
[0099] Example 4 Analysis of the Inhibitory Types of α-glucosidase by Quorum Sensing Peptide GIVL
[0100] Using yeast α-glucosidase (0.2 U / mL) as the enzyme source and p-nitrophenyl-α-D-pyranoglucopyranoside (pNPG) (0.5, 1, 2, 2.5, 3, and 4 mM) as the substrate, the Lineweaver-Burk curve of the quorum sensing peptide GIVL on α-glucosidase was drawn and the inhibition mode was determined by linear regression. The maximum reaction rate (Vmax) and Michaelis-Menten constant (Km) were calculated according to the following Michaelis-Menten equation.
[0101] The accompanying figure refers to the following formula:
[0102] and
[0103] The Lineweaver-Burk double reciprocal plot determined the type of inhibition of α-glucosidase by the quorum sensing peptide GIVL. As shown in Figure 4, both the Vmax and Km values decreased with increasing concentration of the quorum sensing peptide GIVL, and all lines were fitted and intersected in the second quadrant, indicating that the quorum sensing peptide GIVL inhibits α-glucosidase in a mixed manner.
[0104] Example 5 Molecular dynamics (MD) simulation of quorum sensing peptides
[0105] Methods: Molecular dynamics (MD) simulations of different GIVL quorum sensing peptide molecules and acarbose with α-glucosidase were performed using the Gromacs 2021.1 tool. The crystal structure of α-glucosidase (MAL32_YEAST) was obtained from the AlphaFold protein structure database (https: / / alphafold.ebi.ac.uk / ) (UniProt ID: P38158). The structure of acarbose was obtained from the PubChem database. The binding mode between the peptide and α-glucosidase was calculated and determined. The dissolved complex was then used as the initial structure for a 100 ns MD simulation using the amber99sb force field. MM-PBSA calculations were performed using gmx_mmpbsa from GROMACS.
[0106] Table 1. Molecular dynamics (MD) simulations of quorum sensing peptides
[0107] Highly anticipated hotspot residues (center_x = 14.007; center_y = 1.684; center_z = -1.899) were predicted and selected for analysis using FIPSDock. Acarbose, an FDA-approved antidiabetic drug and a microbial α-glucosidase inhibitor, was found to bind to this hotspot. As shown in Table 1, all eight quorum sensing peptides exhibited similar interactions and potential inhibitory effects on α-glucosidase, with comparable binding energies to acarbose, indicating potential hypoglycemic effects.
[0108] Example 6 Quorum Sensing Peptide GIVL Improves Glucose-Insulin Homeostasis in T2D Mice
[0109] After revealing the inhibitory effect of GIVL on α-glucosidase in vitro, the hypoglycemic effect of GIVL was further studied in animal models.
[0110] Animal experimentation: All experiments were performed using C57BL / 6J mice (male, 3 to 4 weeks old) obtained from Changsheng Biotechnology Co., Ltd., Benxi, China. All experimental mice were maintained in a pathogen-free environment (12-h light / dark cycle, 23 ± 2°C temperature, and 60 ± 5% humidity) with sterile water and standard chow. To reduce the heterogeneity of the gut microbiota, mice were randomly divided into five groups of eight after one week of adaptive feeding (NCD: normal mice fed a standard chow; HFD: type 2 diabetic mice fed a high-fat diet; HFD+LG: type 2 diabetic mice fed a high-fat diet plus GIVL at 50 mg / kg body weight / day; HFD+HG: type 2 diabetic mice fed a high-fat diet plus GIVL at 200 mg / kg body weight / day; HFD+Acar: type 2 diabetic mice fed a high-fat diet plus acarbose at 20 mg / kg body weight / day). Except for the NCD group, mice were intraperitoneally injected with streptozotocin (STZ, 65 mg / kg body weight) to induce type 2 diabetes (T2D) and maintained stable for 3 to 4 weeks. The body weight and blood glucose of the mice were collected weekly to monitor the severity of the disease. Insulin in the serum was detected using a commercial ELISA kit (Biotech, Shanghai, China). After an overnight fast, the mice were gavaged with glucose (2 g / kg body weight) for OGTT or intraperitoneally injected with insulin (0.75 IU / kg body weight) for ITT. Blood glucose was then collected at 0, 30, 60, 90, and 120 minutes using a glucometer ( Performa) to measure blood sugar levels.
[0111] After 10 weeks of continuous administration, the levels of fasting blood glucose (FBG) and plasma insulin (FINS) in each group were measured, and oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were performed. The test results are shown in Figure 5. Compared with the HFD group, the FBG and FINS levels of mice in the HFD+HG group were significantly reduced (Figures 5a and 6b). In addition, compared with the HFD group, the mice in the HFD+HG group showed a stronger ability to handle the circulatory ip glucose load during the OGTT under HFD feeding (Figure 5c). Correspondingly, compared with the HFD group, the mice in the HFD+HG group had significantly improved insulin sensitivity during the ITT (Figure 5d). These data indicate that GIVL feeding to mice significantly improved glucose intolerance and insulin resistance caused by a high-fat diet (HFD) in mice, and has an auxiliary blood sugar-lowering effect.
[0112] Example 7 Quorum Sensing Peptide GIVL Regulates the Composition of the Intestinal Microbiome
[0113] Metagenomic sequencing and annotation: DNA was extracted from the fecal samples of each group of mice in Example 6 using QIAamp-DNA Mini Kit (QSK) according to the manufacturer's instructions and sequenced using Illumina Novaseq6000 at Wekemo Technology Group Co., Ltd.
[0114] Bioinformatics analysis: The QIIME software package was used for bioinformatics analysis of the sequences. 1) Data quality control: Trimmomatic software was used to remove adapters and low-quality sequences from the raw data, the remaining reads were filtered according to the host genome, and Bowtie283 was used to obtain valid sequences; 2) Species annotation: Kraken285 software was used to annotate and classify the metagenomic sequencing data, and Bracken was used to estimate the species level and relative abundance of the metagenomic samples. 3) Functional annotation based on readings: Annotation information and relative abundance tables based on the HUMAnN2 functional database were obtained in UniRef 90ID. Specifically, linear discriminant analysis (LEfSe) was performed to compare the differences in species composition between the groups in Example 6.
[0115] Fecal short-chain fatty acids (SCFAs) analysis: Gas chromatography / mass spectrometry (GC-MS) was used on an Agilent DB-FFAP platform (G2790A) to quantify fecal SCFAs in each group of mice in Example 6.
[0116] Analysis of cell density in fermentation broth and fecal short-chain fatty acids (SCFAs): Cell density was monitored by measuring the optical density (OD) at 600 nm using a spectrophotometer (Thermo Spectronic, USA). The cells in the fermentation broth of the wild-type and mutant Clostridium tyrobutyricum in Example 2 were centrifuged at 12,000 × g for 10 minutes and then removed. The supernatant was filtered through a 0.22 μm PVDF syringe filter. The filtered samples were then analyzed for acids (acetic and butyric acid) by gas chromatography (Agilent G2790A, USA).
[0117] Experimental results: Metagenomic analysis showed that at the phylum level, the HFD+HG group showed significantly elevated levels of lactic acid bacteria abundance compared to the HFD group (Figure 6a). Subsequent LEfSe (linear discriminant analysis effect size) analysis was performed to compare the differences in intestinal bacterial genera between the different intervention groups. Compared with the HFD group, the Bifidobacterium genus, especially the Pseudomonas aeruginosa genus, was significantly increased in the HFD+HG group (Figure 6b). Pseudomonas aeruginosa is widely distributed in the intestines of mammals and is a key intestinal commensal bacterial species that regulates mucosal and systemic immune cells by producing the metabolite inosine. In addition, GIVL treatment showed an increase in the abundance of SCFAs-producing microorganisms, primarily Dysosmobacter (Figure 6c). SCFAs analysis showed that acetate production increased 43-fold in the HFD+HG group compared to the HFD group. The increase in acetate may help maintain intestinal balance by triggering an immune response to harmful bacteria. The HFD group showed a deficiency in butyrate production, while the other intervention groups, particularly the HFD+HG group, showed a significant increase in butyrate concentrations (Figure 6d). In addition, GIVL was closely correlated with SCFA levels. LC-HRMS analysis of serum bottle culture supernatants showed that GIVL accumulated in the supernatants of wild-type and ΔagrD-agrD mutant Clostridium tyrobutyricum, but was not detected in the ΔagrD mutant. Similarly, the levels of SCFAs in the supernatants of the wild-type and ΔagrD-agrD mutant were high, but very low in the ΔagrD mutant (Figure 6e). These results indicate that GIVL promotes SCFA production and further provide supportive evidence that GIVL supplementation increases the amount of SCFAs in mouse feces. These results suggest that GIVL may play a key role in regulating SCFA production and the composition of the gut microbiome. Manipulating the secretion of QSPs by the gut microbiota is a novel and potentially powerful strategy to alter host physiological status. Since GIVL is derived from the probiotic bacterium Clostridium tyrobutyricum, genetic engineering and synthetic biology can be used to modify the strain to produce higher levels of beneficial QSPs, thereby achieving disease treatment. Furthermore, natural GIVL or other peptides modified from GIVL can serve as starting building blocks for chemical and / or genetic modification to achieve drug optimization and further enhance drug efficacy.
[0118] Example 8 Effect of Clostridium tyrobutyricum on blood glucose levels
[0119] SPF-grade C57BL / 6J mice were adaptively raised for one week before grouping and dosing. Qualified mice were randomly divided into three groups: a blank group, a negative control group, and a Clostridium tyrobutyricum treatment group, with 6 mice in each group. After grouping, mice in the negative control group and the Clostridium tyrobutyricum treatment group were intraperitoneally injected with streptozotocin (STZ, 65 mg / kg body weight) to induce type 2 diabetes. At the same time, the Clostridium tyrobutyricum treatment group was gavage-fed with Clostridium tyrobutyricum fermentation broth cultured in fermentation medium every day until the end of the experiment. The blank group and the negative control group were given equal volumes of fermentation medium solution after modeling until the end of the experiment. The food intake, water intake, and urine output of the mice were observed weekly and blood glucose levels were tested to monitor the severity of the disease.
[0120] Statistical Analysis: Plotting and data analysis were performed using Origin Pro 9.0 and SPSS Statistics 25.0, respectively. All data are presented as mean ± standard deviation (SD). One-way analysis of variance was used for statistical comparisons between groups; P values < 0.05 were considered significant.
[0121] Experimental Results: During the experiment, mice gavage-treated with Clostridium tyrobutyricum showed no discomfort, ate and drank water, and grew and developed normally. This demonstrates that feeding Clostridium tyrobutyricum is safe and non-toxic. Furthermore, as shown in Figure 7, fasting blood glucose levels were lower in the C. tyrobutyricum-treated group compared to the negative control group, indicating that C. tyrobutyricum has the potential to lower blood glucose levels. In summary, we have found that stably colonizing the intestines of diabetic mice or humans with wild-type or engineered mutant C. tyrobutyricum as a synthetic microbial gut microbiota, for example, by continuously releasing GIVL and SCFAs in the intestine, could be an effective strategy for treating diabetes while avoiding continuous medication and over-dependence. Clostridium tyrobutyricum, with its potential blood glucose-lowering probiotic properties, offers simple fermentation conditions, low industrialization costs, and broad market prospects, making it a probiotic strain with significant economic value.
[0122] Finally, it should be noted that the above implementation methods and examples are only preferred implementation methods of the present invention and are only used to explain the present invention rather than to limit the present invention. Changes, substitutions, modifications, etc. made by those skilled in the art without departing from the spirit of the present invention should fall within the scope of protection of the present invention.
Claims
1. A quorum sensing peptide derived from Clostridium, characterized in that The quorum sensing peptide is an amino acid sequence as shown in SEQ ID NO.1 (GIVLVPTSLVSG), or an amino acid sequence having at least 50% sequence identity with SEQ ID NO.
1.
2. The quorum sensing peptide according to claim 1, characterized in that The nucleic acid molecule encoding the quorum sensing peptide having an amino acid sequence as shown in SEQ ID NO.1 has a nucleotide sequence as shown in SEQ ID NO.2: ATGAAATTTTTAAAAAGTTCTTTAACAAAAAAATCAATGAAAATGATAGGTTCCTTAGCATTATTTTTAGGGGGAATAGTGTTAGTACCAACATCGCTTGTTAGTGGACATCAACCAAAATGCCCTGATGAGTTATTAAAGTAA.
3. The quorum sensing peptide according to claim 1, characterized in that The nucleic acid molecule of the secretion and post-translation modification amino acid sequence of the quorum sensing peptide shown in SEQ ID NO.1 has a nucleotide sequence as shown in SEQ ID NO.3:.
4. The method for preparing a quorum sensing peptide derived from Clostridium according to any one of claims 1 to 3, characterized in that: The method is prepared by fermentation of Clostridium tyrobutyricum, and comprises the following steps: Step 1, collection of fermentation broth: picking a single colony of Clostridium tyrobutyricum, inoculating it into a liquid Clostridium fortified culture medium, culturing it for 24 to 36 hours, inoculating it into a fermentation tank containing fermentation medium, fermenting it for 24 to 120 hours, and collecting the cell-free supernatant by centrifugation; Step 2, pretreatment: add acid solution to the supernatant, let stand at 4°C for 8-16 hours, collect the precipitate by centrifugation, dry under ventilation, grind to obtain the precipitate powder, add methanol to obtain the filtrate containing the quorum sensing peptide; Step 3, reverse phase chromatography separation and semi-preparation: use a ReSource reverse phase chromatography column to desalt with pure methanol, load the filtrate obtained in step 2 onto the system, and collect the components corresponding to the elution peak; Step 4, separation, purification and structural identification: The components separated in step 3 were filtered, desalted and concentrated by nanofiltration, and then separated and purified by HILIC chromatography. The collected components were freeze-dried and analyzed and identified by Nano-LC-ESI-MS / MS to obtain the quorum sensing peptide GIVL.
5. The method for preparing a quorum sensing peptide derived from Clostridium according to any one of claims 1 to 3, characterized in that: The solid phase synthesis method is used for preparation, comprising the following steps: Step 1, resin activation: starting from the C-terminal An, the resin is placed in the reaction column and soaked; Step 2, deprotection: After the resin is soaked, the solution is removed and a deprotection reaction is performed with piperidine; Step 3, weighing materials: weighing the amino acid, condensing agent and N-methylmorpholine required for the next step; Step 4, deprotection: After deprotection is completed, wash with dimethylformamide, detect the deprotection color, and record it; Step 5, adding materials: after the detection is completed, add the amino acid in step 3, then add the reaction solution, alkali and N-methylmorpholine in sequence, adjust the gas evenly, and start the reaction; Step 6, detection: After the reaction is completed, the reaction solution is removed, and it is washed with dimethylformamide to detect whether the reaction is complete; Step 7, if the reaction is complete, repeat steps 2 to 6 to connect the next amino acid; if the reaction is not complete, soak the resin in dichloromethane without eluting the protection, and continue to connect the amino acid in this step until it is connected.
6. Use of the quorum sensing peptide derived from Clostridium according to any one of claims 1 to 3 or Clostridium tyrobutyricum producing the quorum sensing peptide in the preparation of medicines and foods for treating or assisting in the treatment of diabetes.
7. Use of Clostridium tyrobutyricum producing the quorum sensing peptide according to any one of claims 1 to 3 in the preparation of medicines and foods for treating or assisting in the treatment of diabetes.
8. Use of a composition comprising the quorum sensing peptide according to any one of claims 1 to 3 and Clostridium tyrobutyricum producing the quorum sensing peptide in the preparation of a medicine or food for treating or assisting in the treatment of diabetes.
9. The use according to claim 6, characterized in that The quorum sensing peptide or the quorum sensing peptide expressed by the nucleic acid molecule treats or assists in treating diabetes by inhibiting α-glucosidase activity or promoting the release of short-chain fatty acids in the intestine.
10. The use according to claim 7 or 8, characterized in that The Clostridium tyrobutyricum or the composition treats diabetes by inhibiting the activity of α-glucosidase or promoting the release of short-chain fatty acids in the intestine.
Citation Information
Patent Citations
Application of clostridium butyrate in preparation for prevention and treatment or adjuvant therapy of hyperglycemia
CN105769928A
Quorum sensing peptide derived from clostridium as well as preparation method and application of quorum sensing peptide
CN116970037A
